(Albany, US) DelveInsight’s “Optic Neuropathy Market Insights, Epidemiology, and Market Forecast-2032″ report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Optic Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key facts of the Optic Neuropathy Market
The most common acute optic neuropathies include ischemic optic neuropathy (ION), optic neuritis and trauma.
It affects patients ages 50 and above, with acute anterior ischemic optic neuropathy (AION) being the most common form of optic neuropathy.
Non-arteritic ischemic optic neuropathy or NAION has an annual incidence of 2.3-10.2/100,000.
The incidence of optic neuropathy is higher in populations located at higher latitudes such as in the Northern United States; Northern and Western Europe; New Zealand and Southern Australia.
As per studies, the annual incidence of optic neuropathy in the United States of America, is estimated as 5 to 6.4 per 100 000, with a prevalence of 115 per 100 000.
Request for Sample Report:
Key benefits of the Optic Neuropathy Market report:
The study provides a detailed review of Optic Neuropathy, including its causes, signs and symptoms, pathophysiology, diagnosis, and current treatments.
Study of the 7MM has offered comprehensive insight into the epidemiology and management of Optic Neuropathy.
Furthermore, an all-inclusive description of both present and emerging Optic Neuropathy treatments is offered, as well as an analysis of future therapies that will have an influence on the current treatment landscape.
The research includes a full evaluation of the Optic Neuropathy market, both historical and anticipated, as well as drug outreach in the 7MM population.
By understanding the trends defining and driving the worldwide Optic Neuropathy market, the study gives you an advantage when formulating business plans.
Optic Neuropathy Overview
Optic neuropathy refers to the damage to the optic nerve typically caused as a result of a change in blood flow. It takes various forms, including traumatic optic neuropathy which occurs as a result of an acute injury to the optic nerve. Outside factors cause damage to the optic nerve and may result in mild-to-severe impairment, or loss of vision entirely. Ischemic optic neuropathy, on the other hand, is caused by a blockage of the blood supply. Symptoms and signs of optic neuropathy include:
Seeing flashing or flickering lights when moving the eyes.
Appearance of colors may be less bold or vivid than normal.
Loss of vision in one eye, either fully or partially.
Pain in the face and eye socket.
A general loss of peripheral vision.
Eye specialists will perform a full evaluation of the eyes and necessary blood tests may be required to test for giant cell arteritis, along with imaging tests may also assist with diagnosis. Non-arteritic ischemic optic neuropathy (NAION) cannot be cured and its treatment is focused around controlling blood pressure and reducing the symptoms that caused it and preventing it from damaging the other eye. Arteric ischemic optic neuropathy treatment also looks at preventing further damage to the other eye and typically involves the use of anti-inflammatory drugs. Treatment depends entirely on the underlying condition or problem that causes the neuropathy and requires a full evaluation from an eye specialist.
Learn more by requesting for sample @ Optic Neuropathy Market Landscape
Optic Neuropathy Market
The report on Optic Neuropathy market outlook assists in developing a detailed understanding of historic, current, and forecasted Optic Neuropathy market trends by analyzing the impact of current Optic Neuropathy therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This section examines the Optic Neuropathy market trend of each marketed drug and late stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, market impact, and key opinion leaders’ perspectives. Optic Neuropathy market statistics are supplied with pertinent tables and graphs to provide a comprehensive picture of the market at a glance. According to DelveInsight, the Optic Neuropathy market in 7MM is expected to undergo significant change between 2019 and 2032.
Optic Neuropathy Companies
Stealth BioTherapeutics Inc.
Regenera Pharma Ltd
Eli Lilly and Company
And Many More
Elamipretide (MTP-131) 1% topical ophthalmic solution
And Many More
Table of Contents
1. Key Insights
2. Executive Summary of Optic Neuropathy
3. Competitive Intelligence Analysis for Optic Neuropathy
4. Optic Neuropathy: Market Overview at a Glance
5. Optic Neuropathy: Disease Background and Overview
6. Patient Journey
7. Optic Neuropathy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Optic Neuropathy Treatment
11. Marketed Products
12. Emerging Therapies
13. Optic Neuropathy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Optic Neuropathy
17. KOL Views
18. Market Drivers
19. Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States